title: RNA Nanoparticles Derived from Three-Way Junction of Phi29 Motor pRNA Are Resistant to I-125 and Cs-131 Radiation.
abstract: Radiation reagents that specifically target tumors are in high demand for the treatment of cancer. The emerging field of RNA nanotechnology might provide new opportunities for targeted radiation therapy. This study investigates whether chemically modified RNA nanoparticles derived from the packaging RNA (pRNA) three-way junction (3WJ) of phi29 DNA-packaging motor are resistant to potent I-125 and Cs-131 radiation, which is a prerequisite for utilizing these RNA nanoparticles as carriers for targeted radiation therapy. pRNA 3WJ nanoparticles were constructed and characterized, and the stability of these nanoparticles under I-125 and Cs-131 irradiation with clinically relevant doses was examined. RNA nanoparticles derived from the pRNA 3WJ targeted tumors specifically and they were stable under irradiation of I-125 and Cs-131 with clinically relevant doses ranging from 1 to 90 Gy over a significantly long time up to 20 days, while control plasmid DNA was damaged at 20 Gy or higher.
authors.affiliation: 1 Nanobiotechnology Center, University of Kentucky , Lexington, Kentucky.|2 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky , Lexington, Kentucky.
authors.forename: Hui
authors.initials: H
authors.lastname: Li
authors.affiliation: 3 Department of Surgery, Markey Cancer Center, University of Kentucky , Lexington, Kentucky.
authors.forename: Piotr G
authors.initials: PG
authors.lastname: Rychahou
authors.affiliation: 2 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky , Lexington, Kentucky.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Cui
authors.affiliation: 1 Nanobiotechnology Center, University of Kentucky , Lexington, Kentucky.|2 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky , Lexington, Kentucky.
authors.forename: Fengmei
authors.initials: F
authors.lastname: Pi
authors.affiliation: 4 Markey Cancer Center, University of Kentucky , Lexington, Kentucky.
authors.forename: B Mark
authors.initials: BM
authors.lastname: Evers
authors.affiliation: 1 Nanobiotechnology Center, University of Kentucky , Lexington, Kentucky.|2 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky , Lexington, Kentucky.|4 Markey Cancer Center, University of Kentucky , Lexington, Kentucky.
authors.forename: Dan
authors.initials: D
authors.lastname: Shu
authors.affiliation: 1 Nanobiotechnology Center, University of Kentucky , Lexington, Kentucky.|2 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky , Lexington, Kentucky.|4 Markey Cancer Center, University of Kentucky , Lexington, Kentucky.
authors.forename: Peixuan
authors.initials: P
authors.lastname: Guo
authors.affiliation: 5 Department of Radiation Medicine, Markey Cancer Center, University of Kentucky , Lexington, Kentucky.
authors.forename: Wei
authors.initials: W
authors.lastname: Luo
mesh_terms: D000818:Animals; D017103:Bacillus Phages / Q000737:chemistry*; D002588:Cesium Radioisotopes; D003110:Colonic Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D058973:Folate Receptors, GPI-Anchored / Q000378:metabolism*; D005492:Folic Acid / Q000737:chemistry / Q000378:metabolism*; D019073:HT29 Cells; D006801:Humans; D007279:Injections, Subcutaneous; D007457:Iodine Radioisotopes; D007624:KB Cells; D051379:Mice; D008819:Mice, Nude; D058990:Molecular Targeted Therapy / Q000379:methods; D053758:Nanoparticles / Q000737:chemistry / Q000378:metabolism*; D009690:Nucleic Acid Conformation; D020871:RNA Stability; D012367:RNA, Viral / Q000737:chemistry / Q000378:metabolism*; D011877:Radionuclide Imaging; D023041:Xenograft Model Antitumor Assays
chemical_list: D002588:Cesium Radioisotopes; D058973:Folate Receptors, GPI-Anchored; D007457:Iodine Radioisotopes; D012367:RNA, Viral; D005492:Folic Acid